Androgen deprivation therapy (ADT) is the major treatment for progressive prostate cancer (PCa). Although ADT has been shown to improve oncological outcomes,1 it is associated with a non-negligible risk of important side effects.1-3 There are numerous well recognized adverse effects of ADT, which include hot flashes (HF), loss of libido, fatigue, gynecomastia, anemia, and osteoporosis. In addition, obesity, insulin resistance, and dyslipidemia were recently suggested to be potential metabolic complications of ADT.4 The long-term use of ADT also has deleterious effects on cardiovascular health.5 Although it has been reported that the use of ADT is significantly associated with an increased risk of acute kidney injury (AKI) in patients with newly diagnosed non-metastatic PCa (mPCa),6 there have been few studies about the outcomes of renal function after the discontinuation of ADT. We reported that renal dysfunction occurred relatively early during ADT and that hypertensive PCa patients that receive ADT are at high risk of developing renal dysfunction.7 Furthermore, we reported that the discontinuation of ADT tended to result in improvements in renal function and that the renal dysfunction caused by 6 months’ ADT is transient.8 However, to the best of our knowledge, no studies have been performed to assess renal function after 2 years of ADT. It would be very interesting to examine whether renal function improves after prolonged ADT.